Impact of local therapy for metastatic prostate cancer - Impact of local therapy for metastatic prostate cancer

Hirosaki University School of Medicine0 sites50 target enrollmentFebruary 1, 2019

Overview

No summary available.

Registry

who.int

Start Date

February 1, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Hirosaki University School of Medicine

•Refuses to give informed consent Deemed to have unresectable disease by surgeon Received ADT for more than 6 months prior to randomization Life expectancy of less than 6 months prior to randomization Known spinal cord compression M1c disease (solid organ metastasis) Deep vein thrombosis (DVT) / pulmonary embolism (PE) in the past 6 months prior to randomization Previous local therapy for prostate cancer Previous chemotherapy for prostate cancer Patients who have chemotherapy, radiotherapy or oral antifungal agents (ketoconazole, itraconazole, fluconazole) within 3 weeks prior to entering the study or those who have not recovered (e.g. back to baseline or grade 1\) from adverse events due to agents administered more than 3 weeks earlier Any drug interactions that are deemed to be medically significant would require a washout of 5\-half\-lives of the interaction agent before enrollment can occur